Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Iopromide I/mL · 1 trial · 2 indications
A subjective assessment of the 'Quality of Image' (QOI) by 3 blinded readers (BR). QOI-Grades used: Excellent - Good - Poor.
| Arm | Type | Description |
|---|---|---|
| Iopromide 370 mg I/mL | EXPERIMENTAL | Iopromide (Ultravist 370 mg I/mL) administered intravenously |
| Iopromide 300 mg I/mL | EXPERIMENTAL | Iopromide (Ultravist 300 mg I/mL) administered intravenously |
| Name | Type | Description |
|---|---|---|
| Iopromide 370 mg I/mL | DRUG | Iopromide (Ultravist 370 mg I/mL) administered intravenously |
| Iopromide 300 mg I/mL | DRUG | Iopromide (Ultravist 300 mg I/mL) administered intravenously |
Inclusion Criteria: * Is at least 18 years old and clinically indicated for a contrast-enhanced CT of the head or body. Exclusion Criteria: * Patients that are less than 18 years old and do not have a clinical indication for a contrast-enhanced CT of the head or body.
Iopromide I/mL is a contrast agent used in computed tomography (CT) imaging. It is administered to enhance the visibility of internal structures during CT scans of the head and body, helping clinicians obtain clearer diagnostic images.
Iopromide I/mL is developed by Bayer AG, a multinational pharmaceutical and life sciences company. Bayer AG trades on the OTC market under the ticker BAYRY.
Iopromide I/mL is in Phase 3 clinical development. It is an investigational agent and has not been approved by the FDA for any indication.
Iopromide I/mL has been studied in a completed Phase 3 trial, NCT00244140, titled "Ultravist: Safety and Efficacy in Computed Tomography of Head and Body." The trial enrolled 435 participants across the United States, Colombia, India, and South Korea.